Cite
Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
MLA
Curigliano, Giuseppe, et al. “Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 30, no. 17, Sept. 2024, p. 3957. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-24-2131.
APA
Curigliano, G., Curigliano, H., Mach, N., Doi, T., Tai, D., Forde, P. M., Sarantopoulos, J., Bedard, P. L., Lin, C.-C., Hodi, F. S., Wilgenhof, S., Santoro, A., Sabatos-Peyton, C. A., Longmire, T. A., Xyrafas, A., Sun, H., Gutzwiller, S., Manenti, L., & Naing, A. (2024). Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 30(17), 3957. https://doi.org/10.1158/1078-0432.CCR-24-2131
Chicago
Curigliano, Giuseppe, Hans Curigliano, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M Forde, John Sarantopoulos, et al. 2024. “Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 30 (17): 3957. doi:10.1158/1078-0432.CCR-24-2131.